To retrospectively analyze the association between the BCL2 gene family expression at the time of AML diagnosis and the patient response to therapy monitored at a later stage, we divided AML into three groups: CR—patients who reached complete remission after the first induction therapy (n = 11); RES—patients resistant to the first induction therapy (n = 8); X—patients who succumbed to the disease during therapy (n = 8) (Table 1). Here, BCL2 is linked to acute myeloid leukemia.